Information Provided By:
Fly News Breaks for July 30, 2019
Jul 30, 2019 | 04:51 EDT
Barclays analyst Jack Meehan upgraded Genomic Health (GHDX) to Equal Weight from Underweight and raised his price target for the shares to $72 from $45. The analyst believes the acquisition by Exact Sciences (EXAS) represents a good return for shareholders.
News For GHDX;EXAS From the Last 2 Days
There are no results for your query GHDX;EXAS